Dry Eye News and Research

RSS

Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.

Bioengineering students develop new device that can detect patients with dry eye

Rice University bioengineering students responded to an ophthalmologist's cry for help with a device to diagnose dry eye, the itching and burning sensation that results when a person doesn't produce enough tears or the tears evaporate too quickly.

26 Apr 2011

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

Merck enters definitive agreement to acquire Inspire

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products.

6 Apr 2011

IOVS journal publishes first global consensus report on MGD

The first global consensus report on meibomian gland dysfunction - a major cause of lid disease and evaporative dry eye - has been published in a special issue of the Investigative Ophthalmology & Visual Science journal.

1 Apr 2011

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology Annual Meeting being held May 1–May 5, 2011, in Fort Lauderdale, Florida.

25 Mar 2011

RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold

RegeneRx Biopharmaceuticals, Inc. announced that it has received a notice from the U.S. Food and Drug Administration (FDA) indicating that, due to non-compliance with FDA's current Good Manufacturing Practice (cGMP) regulations by its contract manufacturer, the Company's Phase 2 clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold.

16 Mar 2011

TearLab provides update on CLIA Waiver categorization application for TearLab Osmolarity System

TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.

5 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

Springtime may cause or worsen dry eye condition

Springtime may be just what the doctor orders for individuals suffering from dry eye condition, a disorder resulting from insufficient tear production or altered tear film composition. According to a study published in Investigative Ophthalmology & Visual Science, a temperature less than 30 degrees Celsius on the eye and eyelid could be the cause for the onset or worsening of the disorder.

4 Mar 2011

Medwell commits $2,000,000 investment in Mimetogen

Medwell Capital Corp. today announced that it has committed to invest up to $2,000,000 in Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately-held, clinical-stage company developing a treatment for dry eye disease. Medwell Capital participated in a Series B equity financing with existing Mimetogen investors, iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica.

25 Feb 2011

RegeneRx listed on MDB’s 'Best & Brightest' innovators for 2011

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been included on MDB Capital Group's "Best & Brightest" innovators list of 150 companies for 2011. Criterion for inclusion is a ranking in the 90th percentile for technology leadership from more than 1,500 companies with U.S. patents granted, as rated by PatentVest®, MDB's proprietary, intellectual property (IP), business intelligence database.

19 Feb 2011

Inspire announces strategic corporate restructuring on its eye care business

Inspire Pharmaceuticals, announced today a strategic corporate restructuring designed to result in the Company focusing activities on its eye care business, allowing it to fully leverage existing commercial capabilities, pipeline assets and related corporate development and licensing opportunities.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

3 Feb 2011

Promising results from TheraTears Nutrition pilot trial in dry eye patients

Advanced Vision Research, Inc. today announced the publication in the journal Cornea of promising results from a pilot trial of dry eye patients taking TheraTears® Nutrition. The study demonstrated a reduction in dry eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears® Nutrition, an optimized blend of medical grade essential omega-3 oils, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and flaxseed oil.

25 Jan 2011

TearLab's Osmolarity test made available at point-of-care

TearLab Corporation and COLA, a private, non-profit clinical laboratory education, consultation and accreditation organization, announced today that they have partnered to help make the TearLab™ Osmolarity System available in the U.S. at the point-of-care.

11 Jan 2011

Study: Tβ4 can protect endothelial progenitor cells

RegeneRx Biopharmaceuticals, reported that a team of cardiovascular researchers in China have shown that Tβ4 can protect endothelial progenitor cells derived from the blood of healthy human volunteers.

7 Jan 2011

Top-line results of TIGER-2 Phase 3 clinical trial for CF treatment

Inspire Pharmaceuticals, Inc. announced today the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis.

3 Jan 2011

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.

23 Dec 2010